TIAA FSB’s Regeneron Pharmaceuticals REGN Stock Holding History

TIAA FSB’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.88M	Sell	2,613 -219	-8%	-$169K	0.01%	259
2023 Q1	$2.33M	Buy	2,832 +47	+2%	+$35.4K	0.01%	240
2022 Q4	$2.01M	Buy	2,785 +936	+51%	+$691K	0.01%	242
2022 Q3	$1.27M	Sell	1,849 -15	-0.8%	-$9.44K	0.01%	272
2022 Q2	$1.1M	Buy	+1,864	New	+$1.21M	﹤0.01%	309
2019 Q1	–	Sell	-10,374	Closed	-$3.88M	–	347
2018 Q4	$3.88M	Sell	10,374 -933	-8%	-$341K	0.02%	168
2018 Q3	$4.57M	Sell	11,307 -276	-2%	-$105K	0.02%	174
2018 Q2	$4M	Sell	11,583 -10	-0.1%	-$3.13K	0.02%	177
2018 Q1	$3.99M	Buy	+11,593	New	+$4.03M	0.02%	173

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TIAA FSB's REGN Position: Q2 2023 in Review

TIAA FSB reduced its Regeneron Pharmaceuticals (REGN) stake by 7.7% in Q2 2023, selling an estimated $169K and leaving 2,613 shares worth $1.88M. The position accounts for 0.01% of the portfolio, ranked #259.

TIAA FSB first reported a position in REGN in Q1 2018 and has held it in 9 quarters since. The position peaked at $4.57M in Q3 2018. 1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

TIAA FSB held 2,613 shares of Regeneron Pharmaceuticals worth $1.88M as of Q2 2023.
TIAA FSB sold 219 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $169K.
Regeneron Pharmaceuticals made up 0.01% of TIAA FSB's portfolio in Q2 2023, its #259 holding.
TIAA FSB first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 9 quarters since.
TIAA FSB's Regeneron Pharmaceuticals position peaked at $4.57M in Q3 2018.
1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on TIAA FSB's 13F filing for Q2 2023, filed 31 Jul 2023.